{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:27:41Z","timestamp":1783132061342,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-022-02489-1","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T21:04:27Z","timestamp":1675976667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Liposomal Doxorubicin: the Sphingomyelin\/Cholesterol System Significantly Enhances the Antitumor Efficacy of Doxorubicin"],"prefix":"10.1208","volume":"24","author":[{"given":"Xianmin","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaituo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"2489_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119446","volume":"584","author":"Y Chen","year":"2020","unstructured":"Chen Y, Du Q, Zou Y, et al. Co-delivery of doxorubicin and epacadostat via heparin coated pH-sensitive liposomes to suppress the lung metastasis of melanoma. Int J Pharm. 2020;584: 119446.","journal-title":"Int J Pharm"},{"key":"2489_CR2","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4\u2013dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050\u20139.","journal-title":"Nat Med"},{"key":"2489_CR3","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Von Hoff","year":"1979","unstructured":"Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710\u20137.","journal-title":"Ann Intern Med"},{"key":"2489_CR4","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2","volume":"32","author":"EA Lefrak","year":"1973","unstructured":"Lefrak EA, Pi\u0165ha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302\u201314.","journal-title":"Cancer"},{"key":"2489_CR5","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0022-2828(87)80392-9","volume":"19","author":"PK Singal","year":"1987","unstructured":"Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol. 1987;19:817\u201328.","journal-title":"J Mol Cell Cardiol"},{"key":"2489_CR6","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0022-2836(64)80115-7","volume":"8","author":"AD Bangham","year":"1964","unstructured":"Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol. 1964;8:660\u20138.","journal-title":"J Mol Biol"},{"key":"2489_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1556-276X-8-102","volume":"8","author":"A Akbarzadeh","year":"2013","unstructured":"Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8:1\u20139.","journal-title":"Nanoscale Res Lett"},{"key":"2489_CR8","doi-asserted-by":"publisher","first-page":"591325","DOI":"10.1155\/2011\/591325","volume":"2011","author":"A Wagner","year":"2011","unstructured":"Wagner A, Vorauer-Uhl K. Liposome technology for industrial purposes. J Drug Deliv. 2011;2011:591325.","journal-title":"J Drug Deliv"},{"key":"2489_CR9","first-page":"751","volume":"15","author":"P Working","year":"1996","unstructured":"Working P, Dayan A. Pharmacological-toxicological expert report CAELYXTM:(stealth\u00ae liposomal doxorubicin HCl). Hum Exp Toxicol. 1996;15:751\u201385.","journal-title":"Hum Exp Toxicol"},{"key":"2489_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1040-8428(00)00107-4","volume":"37","author":"MR Ranson","year":"2001","unstructured":"Ranson MR, Cheeseman S, White S, Margison J. Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Crit Rev Oncol Hematol. 2001;37:115\u201320.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2489_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemphyslip.2020.105036","volume":"235","author":"M Rastogi","year":"2021","unstructured":"Rastogi M, Saha RN, Alexander A, et al. Role of stealth lipids in nanomedicine-based drug carriers. Chem Phys Lipids. 2021;235: 105036.","journal-title":"Chem Phys Lipids"},{"key":"2489_CR12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","volume":"24","author":"DN Waterhouse","year":"2001","unstructured":"Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf. 2001;24:903\u201320.","journal-title":"Drug Saf"},{"key":"2489_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00003495-199700544-00005","volume":"54","author":"A Gabizon","year":"1997","unstructured":"Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs. 1997;54:15\u201321.","journal-title":"Drugs"},{"key":"2489_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1023\/A:1014428720551","volume":"20","author":"KM Skubitz","year":"2002","unstructured":"Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil\u2122) in renal cell cancer. Invest New Drugs. 2002;20:101\u20134.","journal-title":"Invest New Drugs"},{"key":"2489_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1526-8209(11)70179-3","volume":"3","author":"K Maung","year":"2002","unstructured":"Maung K, O\u2019Shaughnessy J, Overmoyer B. Pegylated liposomal doxorubicin (Doxil\u00ae) versus doxorubicin for first-line treatment of metastatic breast cancer. Clin Breast Cancer. 2002;3:183\u20134.","journal-title":"Clin Breast Cancer"},{"key":"2489_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118706","volume":"571","author":"J Ding","year":"2019","unstructured":"Ding J, Zhao D, Hu Y, et al. Terminating the renewal of tumor-associated macrophages: a sialic acid-based targeted delivery strategy for cancer immunotherapy. Int J Pharm. 2019;571: 118706.","journal-title":"Int J Pharm"},{"key":"2489_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijpharm.2017.03.034","volume":"523","author":"S Zhou","year":"2017","unstructured":"Zhou S, Zhang T, Peng B, et al. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity. Int J Pharm. 2017;523:203\u201316.","journal-title":"Int J Pharm"},{"key":"2489_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.accb.2018.09.001","volume":"75","author":"R Schauer","year":"2018","unstructured":"Schauer R, Kamerling JP. Exploration of the sialic acid world. Adv Carbohydr Chem Biochem. 2018;75:1\u2013213.","journal-title":"Adv Carbohydr Chem Biochem"},{"key":"2489_CR19","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41577-018-0004-8","volume":"18","author":"GD Brown","year":"2018","unstructured":"Brown GD, Willment JA, Whitehead L. C-type lectins in immunity and homeostasis. Nat Rev Immunol. 2018;18:374\u201389.","journal-title":"Nat Rev Immunol"},{"key":"2489_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3892\/ol.2016.5431","volume":"13","author":"D Ding","year":"2017","unstructured":"Ding D, Yao Y, Zhang S, et al. C-type lectins facilitate tumor metastasis. Oncol Lett. 2017;13:13\u201321.","journal-title":"Oncol Lett"},{"key":"2489_CR21","doi-asserted-by":"crossref","unstructured":"Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. In: Seminars in immunopathology. Springer;\u00a02013. p. 585\u2013600.","DOI":"10.1007\/s00281-013-0367-7"},{"key":"2489_CR22","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.3389\/fimmu.2018.02472","volume":"9","author":"J Grabowska","year":"2018","unstructured":"Grabowska J, Lopez-Venegas MA, Affandi AJ, Den Haan JM. CD169+ macrophages capture and dendritic cells instruct: the interplay of the gatekeeper and the general of the immune system. Front Immunol. 2018;9:2472.","journal-title":"Front Immunol"},{"key":"2489_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jconrel.2021.06.027","volume":"337","author":"C Li","year":"2021","unstructured":"Li C, Qiu Q, Gao X, et al. Sialic acid conjugate-modified liposomal platform modulates immunosuppressive tumor microenvironment in multiple ways for improved immune checkpoint blockade therapy. J Control Release. 2021;337:393\u2013406.","journal-title":"J Control Release"},{"key":"2489_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121684","volume":"620","author":"M Chen","year":"2022","unstructured":"Chen M, Wu W, Wang S, et al. Neutrophils as emerging immunotherapeutic targets: indirect treatment of tumors by regulating the tumor immune environment based on a sialic acid derivative-modified nanocomplex platform. Int J Pharm. 2022;620: 121684.","journal-title":"Int J Pharm"},{"key":"2489_CR25","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1021\/bi00122a017","volume":"31","author":"TJ McIntosh","year":"1992","unstructured":"McIntosh TJ, Simon SA, Needham D, Huang CH. Structure and cohesive properties of sphingomyelin\/cholesterol bilayers. Biochemistry. 1992;31:2012\u201320.","journal-title":"Biochemistry"},{"key":"2489_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0009-3084(99)00072-9","volume":"102","author":"Y Barenholz","year":"1999","unstructured":"Barenholz Y, Thompson TE. Sphingomyelin: biophysical aspects. Chem Phys Lipids. 1999;102:29\u201334.","journal-title":"Chem Phys Lipids"},{"key":"2489_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ajps.2014.09.004","volume":"10","author":"J Li","year":"2015","unstructured":"Li J, Wang X, Zhang T, et al. A review on phospholipids and their main applications in drug delivery systems. Asian J Pharm Sci. 2015;10:81\u201398.","journal-title":"Asian J Pharm Sci"},{"key":"2489_CR28","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/bjc.1995.430","volume":"72","author":"M Webb","year":"1995","unstructured":"Webb M, Harasym T, Masin D, et al. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer. 1995;72:896\u2013904.","journal-title":"Br J Cancer"},{"key":"2489_CR29","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/jps.20332","volume":"94","author":"SC Semple","year":"2005","unstructured":"Semple SC, Leone R, Wang J, et al. Optimization and characterization of a sphingomyelin\/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci. 2005;94:1024\u201338.","journal-title":"J Pharm Sci"},{"key":"2489_CR30","doi-asserted-by":"publisher","first-page":"5534","DOI":"10.1021\/acs.molpharmaceut.8b00687","volume":"15","author":"M Liu","year":"2018","unstructured":"Liu M, Luo X, Qiu Q, et al. Redox-and pH-sensitive glycan (polysialic acid) derivatives and F127 mixed micelles for tumor-targeted drug delivery. Mol Pharm. 2018;15:5534\u201345.","journal-title":"Mol Pharm"},{"key":"2489_CR31","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.actbio.2021.07.063","volume":"134","author":"J Ding","year":"2021","unstructured":"Ding J, Sui D, Liu M, et al. Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil\/monocyte infiltration for tumor therapy. Acta Biomater. 2021;134:702\u201315.","journal-title":"Acta Biomater"},{"key":"2489_CR32","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S0005-2736(98)00077-7","volume":"1372","author":"MS Webb","year":"1998","unstructured":"Webb MS, Saxon D, Wong FM, et al. Comparison of different hydrophobic anchors conjugated to poly (ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta. 1998;1372:272\u201382.","journal-title":"Biochim Biophys Acta"},{"key":"2489_CR33","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ijpharm.2019.01.005","volume":"558","author":"H Zheng","year":"2019","unstructured":"Zheng H, Li J, Wang M, et al. Exhausting tumor associated macrophages with sialic acid-polyethyleneimine-cholesterol modified liposomal doxorubicin for enhancing sarcoma chemotherapy. Int J Pharm. 2019;558:187\u2013200.","journal-title":"Int J Pharm"},{"key":"2489_CR34","first-page":"6","volume":"1","author":"S Karmakar","year":"2012","unstructured":"Karmakar S, Bhaumik SK, Paul J, De T. Leishmania donovani cell surface sialoglycans regulate susceptibility for siglec mediated macrophage invasion and parasite survival. J Mol Biochem. 2012;1:6\u201320.","journal-title":"J Mol Biochem"},{"key":"2489_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0009-3084(99)00071-7","volume":"102","author":"JP Slotte","year":"1999","unstructured":"Slotte JP. Sphingomyelin\u2013cholesterol interactions in biological and model membranes. Chem Pys Lipids. 1999;102:13\u201327.","journal-title":"Chem Pys Lipids"},{"key":"2489_CR36","doi-asserted-by":"crossref","unstructured":"Boman NL, Cullis PR, Mayer LD,\u00a0et al. Liposomal vincristine: the central role of drug retention in defining therapeutically optimized anticancer formulations. In: Long circulating liposomes: old drugs, new therapeutics. Springer; 1998. p. 29\u201349.","DOI":"10.1007\/978-3-662-22115-0_3"},{"key":"2489_CR37","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1042\/bj2380647","volume":"238","author":"C Bhuvaneswaran","year":"1986","unstructured":"Bhuvaneswaran C, Mitropoulos KA. Effect of liposomal phospholipid composition on cholesterol transfer between microsomal and liposomal vesicles. Biochem J. 1986;238:647\u201352.","journal-title":"Biochem J"},{"key":"2489_CR38","first-page":"539","volume":"226","author":"T Allen","year":"1983","unstructured":"Allen T, Everest J. Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. J Pharmacol Exp Ther. 1983;226:539\u201344.","journal-title":"J Pharmacol Exp Ther"},{"key":"2489_CR39","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/0024-3205(82)90455-6","volume":"30","author":"J Senior","year":"1982","unstructured":"Senior J, Gregoriadis G. Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. Life Sci. 1982;30:2123\u201336.","journal-title":"Life Sci"},{"key":"2489_CR40","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1080\/10717544.2018.1474973","volume":"25","author":"X Luo","year":"2018","unstructured":"Luo X, Hu L, Zheng H, et al. Neutrophil-mediated delivery of pixantrone-loaded liposomes decorated with poly (sialic acid)\u2013octadecylamine conjugate for lung cancer treatment. Drug Deliv. 2018;25:1200\u201312.","journal-title":"Drug Deliv"},{"key":"2489_CR41","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.addr.2008.08.005","volume":"60","author":"JD Byrne","year":"2008","unstructured":"Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615\u201326.","journal-title":"Adv Drug Deliv Rev"},{"key":"2489_CR42","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1189\/jlb.0609385","volume":"86","author":"G Solinas","year":"2009","unstructured":"Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065\u201373.","journal-title":"J Leukoc Biol"},{"key":"2489_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"B-Z Qian","year":"2010","unstructured":"Qian B-Z, Pollard JWJC. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39\u201351.","journal-title":"Cell"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-022-02489-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-022-02489-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-022-02489-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T15:06:25Z","timestamp":1676300785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-022-02489-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["2489"],"URL":"https:\/\/doi.org\/10.1208\/s12249-022-02489-1","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"assertion":[{"value":"20 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"64"}}